Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart
Status:
Completed
Trial end date:
2019-04-16
Target enrollment:
Participant gender:
Summary
This pilot clinical trial will examine the effects of intranasal insulin aspart on cognition,
daily function, blood and cerebral spinal fluid markers of Alzheimer's disease, and amyloid
deposition in the brain. Participants will be randomly assigned to receive insulin aspart or
placebo during a 12-week treatment period.
Phase:
Phase 1
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
General Electric National Institute on Aging (NIA)